LeadMuta key facts
- Developer of innovative drugs designed to accelerate small-molecule research from target identification through preclinical optimization.
- It has raised $16.1M; the latest was Early Stage VC ($14.5M) in Mar 2026.
- Notable investors include SND Ventures Group, Zhengxuan Investment, GSR United Capital, Suzhou Nanhui Zhongcheng Entrepreneurship Investment, Insigma Technology — 12 tracked in total.
- Status: Privately Held (backing).
Who backs LeadMuta
12+- ·The complete investor list: 12 names
- ·Watch LeadMuta: the Monday email on marks, rounds and moves
LeadMuta funding rounds
No funding rounds for LeadMuta are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
LeadMuta investors
12 investors are on record for LeadMuta, including SND Ventures Group, Zhengxuan Investment, GSR United Capital and Suzhou Nanhui Zhongcheng Entrepreneurship Investment.
About LeadMuta
Developer of innovative drugs designed to accelerate small-molecule research from target identification through preclinical optimization. The company offers integrated capabilities spanning computational chemistry workflows of small molecules and to create a new drug research and development pipeline based on artificial intelligence, computational chemistry, medicinal chemistry, and other disciplines, enabling patients to have new drugs sooner.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2021
- Website
- leadmuta.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
LeadMuta doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.